Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase

Area of Science:

• Biochemistry
• Oncology
• Medicinal Chemistry

Background:

• Ras proteins are crucial in human cancers, with mutations found in over 50% of colon and 90% of pancreatic carcinomas.
• Ras protein activity depends on post-translational modification, starting with farnesylation catalyzed by farnesyltransferase (FTase).
• FTase inhibitors are investigated as potential antitumor therapeutics.

Purpose of the Study:

• To identify and characterize novel inhibitors of farnesyltransferase (FTase).
• To explore structure-activity relationships of FTase inhibitors lacking a cysteine residue.
• To evaluate the efficacy of identified inhibitors in a biological model dependent on ras pathway activation.

Main Methods:

• High-volume screening of compounds to identify FTase inhibitors.
• Synthesis and structural modification of lead compounds based on structure-activity relationships.
• Assay of FTase inhibition using rat brain enzyme and determination of IC50 values.
• Assessment of inhibitor activity in Xenopus oocyte maturation, a ras-dependent process.

Main Results:

• PD083176, a pentapeptide derivative, was identified as a potent FTase inhibitor with an IC50 of 20 nM.
• Structure-activity relationship studies yielded potent FTase inhibitors that do not require a cysteine residue.
• The parent compound PD083176 effectively inhibited insulin-induced Xenopus oocyte maturation at 5 pmol/oocyte.

Conclusions:

• Novel cysteine-free FTase inhibitors have been developed.
• These inhibitors demonstrate potent activity against FTase and block ras-dependent signaling.
• The identified compounds represent promising candidates for anticancer drug development targeting the ras pathway.